New primary sclerosing cholangitis treatment to target ACLY enzyme
With ESP-1336 as their lead candidate, Esperion Therapeutics is developing new treatments for primary sclerosing cholangitis (PSC) by targeting an enzyme called ACLY.
Marisa Wexler, MS, Senior Science Writer — 
Articles by Marisa Wexler
FDA, Health Canada reviewing semaglutide for liver disease MASH
The U.S. Food and Drug Administration and Health Canada are reviewing Novo Nordisk‘s requests to approve semaglutide’s under-the-skin formulation, at a dose of 2.4…
Statins reduce risk of liver cancer, death in chronic viral hepatitis
Treatment with certain types of cholesterol-lowering drugs called statins may help reduce the risk of cirrhosis, or irreversible liver scarring, liver cancer, and death in…
Boosting IRF1 protein prevents growth of hepatitis D virus in study
Increasing the levels of a protein called IRF1 helps suppress infection of the hepatitis D virus (HDV) and its growth inside of cells, a new…
American Liver Foundation gears up for advocacy summit
Patients, caregivers, and supporters will head to Washington later this month to advocate for policies to improve life for people living with fatty liver…
COVID-19 complicates vascular problems in woman with Alagille
A 34-year-old woman with Alagille syndrome and vascular problems — who had been implanted with a stent for her narrowed pulmonary arteries — experienced…
First patient dosed in Phase 3 trial of hepatitis C combination therapy
The first participant has been dosed in a Phase 3 clinical trial testing Atea Pharmaceuticals’ combination therapy bemnifosbuvir and ruzasvir in adults with chronic…
Liver tissue analysis may help ID, distinguish PFIC types: Study
Analyzing the presence of different proteins in liver tissue under a microscope can be used to help diagnose progressive familial intrahepatic cholestasis (PFIC) and…
MASLD tied to higher mortality risk from nearly every cause
Compared with the general population, the risk of death is nearly twice as high in people with metabolic dysfunction-associated steatotic liver disease (MASLD), a form…
Phase 1 trial of gene-editing therapy for hepatitis B cleared in US
Precision Biosciences has been given the go-ahead to expand a Phase 1 clinical trial testing PBGENE-HBV, its gene-editing therapy for chronic hepatitis…
